PTP4A1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2211505	0.70	3/20
SCHEMBL5618661	0.70	3/20
SCHEMBL5618664	0.70	3/20
SCHEMBL7153194	0.63	2/20
SCHEMBL7153196	0.63	2/20
SCHEMBL2215142	0.62	2/20
SCHEMBL4328828	0.61	2/20
SCHEMBL5164387	0.57	2/20
SCHEMBL6280784	0.51	2/20
SCHEMBL6288771	0.51	2/20
SCHEMBL7794250	0.51	2/20
SCHEMBL5595450	0.47	2/20
SCHEMBL2211858	0.47	2/20
SCHEMBL4488546	0.46	2/20
SCHEMBL4488550	0.46	2/20
SCHEMBL7071553	0.46	2/20
SCHEMBL7071555	0.46	2/20
SCHEMBL1341449	0.44	2/20
SCHEMBL4325323	0.44	2/20
SCHEMBL4325325	0.44	2/20

Clinical trials — most relevant to PTP4A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy	PHASE3	UNKNOWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Leniolisib for Immune Dysregulation in PIDs	PHASE2	ACTIVE_NOT_RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma	PHASE2	ACTIVE_NOT_RECRUITING
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies	nan	UNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children	nan	NOT_YET_RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies	nan	NOT_YET_RECRUITING
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Immune Function and the Progression to T1D	nan	RECRUITING
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes	nan	RECRUITING
Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)	nan	WITHDRAWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
NIAID Clinical Center Genomics Opportunity Protocol	nan	COMPLETED
The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTP4A1 binder may also engage these)

Protein	Name	Similarity
Q9TSM6	—	1.000	Q9TSM6 →
Q63739	—	1.000	Q63739 →
Q78EG7	—	1.000	Q78EG7 →
Q5R7J8	—	1.000	Q5R7J8 →
O61722	—	1.000	O61722 →
A2VDT1	—	1.000	A2VDT1 →
PTP4A2	Protein tyrosine phosphatase type IVA 2	1.000	landscape →
Q6P9X4	—	1.000	Q6P9X4 →
PTP4A3	Protein tyrosine phosphatase type IVA 3	1.000	landscape →
O70274	—	1.000	O70274 →
Q9D658	—	1.000	Q9D658 →
Q54DU9	—	0.998	Q54DU9 →
Q86IL4	—	0.997	Q86IL4 →
Q4CUJ8	—	0.993	Q4CUJ8 →
Q4QEZ7	—	0.987	Q4QEZ7 →
P0DOQ6	—	0.986	P0DOQ6 →
A0A7H0DN78	—	0.986	A0A7H0DN78 →
Q85297	—	0.986	Q85297 →
P80994	—	0.986	P80994 →
P20495	—	0.986	P20495 →
P07239	—	0.985	P07239 →
Q9ZR37	—	0.985	Q9ZR37 →
P0DOQ5	—	0.984	P0DOQ5 →
B4NBB0	—	0.983	B4NBB0 →
Q5I142	—	0.983	Q5I142 →
Q6GQJ8	—	0.983	Q6GQJ8 →
Q5XI69	—	0.983	Q5XI69 →
PFKFB2	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2	0.982	landscape →
Q8IG39	—	0.982	Q8IG39 →
A4D256	—	0.982	A4D256 →